Patrick S. Parfrey mainly focuses on Internal medicine, Surgery, Cardiology, Kidney disease and Genetics. His Internal medicine study frequently draws parallels with other fields, such as Endocrinology. His Surgery research incorporates themes from Diabetes mellitus, Creatinine and Myocardial infarction.
His Cardiology study integrates concerns from other disciplines, such as Prospective cohort study and Left ventricular hypertrophy. Patrick S. Parfrey has included themes like Hazard ratio, Nephropathy, Anemia and Intensive care medicine in his Kidney disease study. In the subject of general Genetics, his work in Genotype, PKD1, Autosomal dominant polycystic kidney disease and Germline mutation is often linked to BBS2, thereby combining diverse domains of study.
The scientist’s investigation covers issues in Internal medicine, Kidney disease, Cardiology, Surgery and Intensive care medicine. His study in Internal medicine focuses on Hemodialysis, Dialysis, Heart failure, Anemia and Colorectal cancer. The Hemodialysis study which covers Cinacalcet that intersects with Cinacalcet Hydrochloride, Clinical trial and Calcimimetic.
In his research on the topic of Kidney disease, Renal function is strongly related with Diabetes mellitus. His work investigates the relationship between Cardiology and topics such as Disease that intersect with problems in Dialysis patients. His Surgery research integrates issues from Muscle hypertrophy and Kidney.
Patrick S. Parfrey mostly deals with Internal medicine, Colorectal cancer, Hemodialysis, Cinacalcet and Kidney disease. The concepts of his Internal medicine study are interwoven with issues in Oncology and Cardiology. In his research, Renal function is intimately related to Framingham Risk Score, which falls under the overarching field of Cardiology.
His research in Hemodialysis tackles topics such as Physical therapy which are related to areas like Medical record, Low back pain and Quality of life. His research integrates issues of Anemia, Intensive care medicine, Dialysis, Type 2 diabetes and Risk factor in his study of Kidney disease. His Cinacalcet Hydrochloride research is multidisciplinary, incorporating perspectives in Endocrinology, Surgery and Intention-to-treat analysis.
Patrick S. Parfrey mainly investigates Internal medicine, Cinacalcet, Hemodialysis, Kidney disease and Cinacalcet Hydrochloride. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Cardiology. The Hemodialysis study combines topics in areas such as Secondary hyperparathyroidism and Hyperphosphatemia.
Patrick S. Parfrey interconnects Nephrology, Diabetes mellitus, Type 2 diabetes, Intensive care medicine and Risk factor in the investigation of issues within Kidney disease. The study incorporates disciplines such as Etelcalcetide, Surgery and Intention-to-treat analysis in addition to Cinacalcet Hydrochloride. His Surgery study incorporates themes from Economic evaluation and Emergency medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clinical epidemiology of cardiovascular disease in chronic renal disease.
Robert N. Foley;Patrick S. Parfrey;Mark J. Sarnak.
American Journal of Kidney Diseases (1998)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A Pfeffer;Emmanuel A. Burdmann;Chao Yin Chen;Mark E. Cooper.
The New England Journal of Medicine (2009)
Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
Robert N. Foley;Patrick S. Parfrey;Patrick S. Parfrey;John D. Harnett;John D. Harnett;Gloria M. Kent;Gloria M. Kent.
Kidney International (1995)
Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study.
Patrick S. Parfrey;Sheila M. Griffiths;Brendan J. Barrett;Michael D. Paul.
The New England Journal of Medicine (1989)
Epidemiology of cardiovascular disease in chronic renal disease.
Foley Rn;Parfrey Ps;Sarnak Mj.
Journal of The American Society of Nephrology (1998)
The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease☆
Robert N. Foley;Patrick S. Parfrey;Patrick S. Parfrey;John D. Harnett;John D. Harnett;Gloria M. Kent;Gloria M. Kent.
American Journal of Kidney Diseases (1996)
Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors
John D. Harnett;Robert N. Foley;Gloria M. Kent;Paul E. Barre.
Kidney International (1995)
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis
Evolve Trial Investigators;Chertow Gm;Block Ga;Correa-Rotter R.
The New England Journal of Medicine (2012)
Preventing Nephropathy Induced by Contrast Medium
Brendan J. Barrett;Patrick S. Parfrey.
The New England Journal of Medicine (2006)
The Clinical Epidemiology of Cardiac Disease in Chronic Renal Failure
Patrick S. Parfrey;Robert N. Foley.
Journal of The American Society of Nephrology (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Minnesota
Memorial University of Newfoundland
University of Toronto
Stanford University
University College London
Grenoble Alpes University
University of Glasgow
Stanford University
Fred Hutchinson Cancer Research Center
Indiana University
Brigham Young University
Amazon (United States)
Bielefeld University
Polytechnic University of Turin
Tsinghua University
Arc International
Max Planck Society
British Antarctic Survey
Washington State University
National Academies of Sciences, Engineering, and Medicine
Jet Propulsion Lab
Federal University of Rio Grande do Norte
Zhejiang University
National Institutes of Health
University of Washington
Czech Academy of Sciences